Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centre for Mendelian Genomics, |
RCV001197796 | SCV001368575 | uncertain significance | Emery-Dreifuss muscular dystrophy 5, autosomal dominant | 2020-04-02 | criteria provided, single submitter | clinical testing | This variant was classified as: Uncertain significance. The available evidence on this variant's pathogenicity is insufficient or conflicting. The following ACMG criteria were applied in classifying this variant: PP3,BP1. |
Labcorp Genetics |
RCV001197796 | SCV002153111 | uncertain significance | Emery-Dreifuss muscular dystrophy 5, autosomal dominant | 2022-10-13 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 931335). This variant has not been reported in the literature in individuals affected with SYNE2-related conditions. This variant is present in population databases (rs765353232, gnomAD 0.003%). This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 5517 of the SYNE2 protein (p.Glu5517Gly). |